Bisrat K. Abraham

Bisrat K. Abraham

Auto-generated profile, based on publicly available information

Bisrat K. Abraham

Pfizer Inc. New York NY USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2026 in The Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
SSSiddhee Anand Sahasrabudhe
Siddhee Anand Sahasrabudhe
SSSatoshi Shoji
Satoshi Shoji
AJAbhijeet S. Jakate
Abhijeet S. Jakate
BABisrat K. Abraham
Bisrat K. Abraham
STSima S. Toussi
Sima S. Toussi
RSRavi Shankar P. Singh
Ravi Shankar P. Singh
There are currently no oral treatment options for infections caused by extended spectrum β‑lactamase‐producing Enterobacterales. Avibactam tomilopil, a novel oral prodrug of avibactam, is being developed in combination with the oral cephalosporin, ceftibuten, as a potential treatment for patients with complicated urinary tract infections (cUTIs). The safety, tolerability, and pharmacokinetic profiles of single and multiple doses of avibactam tomilopil (900 to 1350 mg) and ceftibuten (400 to 1600 mg), alone and/or in combination were evaluated in three Phase 1 trials in healthy participants. Avibactam tomilopil was rapidly metabolized to active avibactam and plasma avibactam exposure increased proportionately with dose. Both avibactam and cis‐ceftibuten had similar plasma half‐lives, and were predominantly renally excreted. While there was negligible food effect on ceftibuten exposures, plasma avibactam exposure in the fed state for a fixed‐dose combination ceftibuten‐avibactam tomilopil tablet was higher compared with the fasted state. Based on joint probability of target attainment simulations using a simultaneous oral ceftibuten‑avibactam tomilopil population pharmacokinetic model, a tablet formulation ceftibuten 400 mg + avibactam tomilopil 1200 mg dosed every 8 h without regard to food is proposed for Phase 3 evaluation in adult patients with cUTIs. Trial registration: NCT03931876; NCT05554237; NCT06593054.